In this issue:A Scientific Approach to Defining, Evaluating, and Treating Pre-Aging With a Cosmetic Regimen Containing a Novel Cosmetic Peptide, Acetyl Dipeptide-31 Amide (AP31)Pre-aging is a relatively new term used…
Read More
INTRODUCTIONIn Nordic European countries, the annual incidence of new cancer cases between 2018 and 2022 was 642.4 per 100,000 in males and 520.3 per 100,000 in females, with a lifetime…
Read More
In this issue:A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal Cancer TherapyPreventing and treating common dermatologic toxicities associated with hormonal cancer therapies is an…
Read More
INTRODUCTIONMelanoma is a deadly malignancy with rising incidence rates over the past 50 years, especially in fairly complected individuals.1 Since 1975, melanoma incidence in the United States has increased by…
Read More
INTRODUCTIONTopical corticosteroids (TCS) are a class of medications frequently used for a wide variety of dermatologic conditions. This type of medication is generally quite effective with a favorable safety profile,…
Read More
INTRODUCTIONBasal cell carcinoma (BCC) is the most common cutaneous nonmelanoma skin cancer worldwide that predominantly appears on sun-exposed skin. Superficial basal cell carcinomas (sBCC) present clinically as erythematous scaly macules…
Read More
INTRODUCTIONAtopic dermatitis (AD) is a chronic inflammatory skin condition characterized by recurrent eczematous lesions and pruritus.1 Beyond its significant impact on patient quality of life, its systemic inflammatory nature may…
Read More
INTRODUCTIONBasal cell carcinoma (BCC) is the most prevalent cancer worldwide.1 The mainstay of treatment is surgical excision or Mohs micrographic surgery but patients may develop advanced BCC such that surgical…
Read More
INTRODUCTIONAging skin frequently shows a decrease in skin firmness/density and may be associated with erythema or uneven skin tone.1 Often, aging skin is accompanied by dermatoporosis or thin, fragile skin.2,3…
Read More
INTRODUCTIONEruptive keratoacanthomas (KAs) and squamous cell carcinomas (SCCs) are recognized side effects of monotherapy with BRAF inhibitors.1 These adverse effects have also been observed with other kinase inhibitors (KI), immune…
Read More
BACKGROUNDActinic keratosis (AK) is a prevalent skin lesion induced by ultraviolet (UV) radiation, serving as a precursor to squamous cell carcinoma (SCC). Ultraviolet A (UVA) rays constitute approximately 95% of…
Read More
INTRODUCTIONImmune checkpoint inhibitors (ICIs) are a form of immunotherapy that have contributed to substantial improvements in both the morbidity and mortality of melanoma and include monoclonal antibodies targeting cytotoxic T-lymphocyte…
Read More
